Consensus on whole-process pharmaceutical care for gadolinium-based contrast agents
- VernacularTitle:钆对比剂全程化药学服务共识
- Author:
Association CLINICAL
1
;
Association EXPERT
1
Author Information
1. Clinical Professional Committee on Rational Drug Use of China Medical Education Association，Expert Committee on Drug Evaluation and Clinical Research of Guangdong Pharmaceutical Association
- Publication Type:Journal Article
- Keywords:
gadolinium-based contrast agents;
rational drug use;
adverse drug reactions;
pharmaceutical care;
whole-process
- From:
China Pharmacy
2023;34(17):2049-2056
- CountryChina
- Language:Chinese
-
Abstract:
In order to promote the rational clinical use of gadolinium-based contrast agents （GBCA） and to provide a reference for physicians to prescribe such contrast agents and for pharmacists to review prescriptions， the consensus working group launched the preparation project of “Consensus on whole-process pharmaceutical care for GBCA” according to domestic and foreign guidelines and consensus. The Zhujiang Hospital of Southern Medical University took the lead and cooperated with clinical experts and pharmaceutical experts from several domestic medical institutions to discuss and summarize the basic pharmacological effect of GBCA， types， pharmacokinetics， pharmacodynamics， indications， contraindications， precautions， usage and dosage， adverse drug reactions， and finally forms the consensus. The main contents of this consensus include an overview of various types of GBCA， rational clinical use of drugs， security management and whole-process pharmaceutical care process， etc.， for reference by physicians and pharmacists in medical institutions at all levels.
